Clinical trials: Open Access
HIV Infections
Pediatric Expanded Access Program-Oral Solution (0831-908)
Monitor the safety and tolerability of efavirenz oral solution in combination with Antiretroviral Therapy for the treatment of patients age 3 to 16 years who have failed therapy or who are intolerant to their current therapy.
- Trial name
- NCT00543530
- Testing
- MK0831
- Sponsor
- Merck Sharp & Dohme LLC
Platelet Activation, Hemodialysis Fistula Thrombosis
Platelet Activation Affecting the Rate of Vascular Access Patency
In the case of cardiovascular diseases such as coronary artery disease, cerebrovascular disease, and peripheral arterial disease, there are many studies that the use of antiplatelet agents is very helpful in improving the…
- Trial name
- NCT05165797
- Testing
- platelet activation factors
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Korea University Anam Hospital
ADHD
Telehealth BPT in DBP Practice
Access to evidence-based psychosocial interventions, particularly Behavioral Parent Training (BPT), for youth with Attention Deficit/Hyperactivity Disorder (ADHD) is limited.
- Trial name
- NCT05301933
- Testing
- Behavioral Parent Training (BPT)
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- NYU Langone Health
Infertility
Efficacy and Safety of Crinone Versus Combination Medication (ACCESS)
The study to compare to the efficacy and safety of Crinone versus combination medication in infertile women receive frozen-thawed embryo transfer (FET) in artificial cycles (AC).
- Trial name
- NCT03858049
- Testing
- Crinone, Duphaston
- Where
- China
- Volunteers
- 172 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Gaucher Disease
Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease
This is an open-label expanded access trial of prGCD in patients with Gaucher disease who require enzyme replacement therapy (ERT) and who have been treated with imiglucerase but for whom the dose has been reduced or discontinued…
- Trial name
- NCT00962260
- Testing
- Plant cell expressed recombinant glucocerebrosidase (prGCD)
- Where
- 15 sites in United States, Israel
- Sponsor
- Pfizer
Pulmonary Arterial Hypertension
Safety and Efficacy of Continued CS1 Treatment of Patients With Pulmonary Arterial Hypertension
CS1-004 will be an extension of the CS1-003 Study. The primary objective of the CS1-004 study is to evaluate long-term safety and tolerability of continued treatment with CS1.
- Trial name
- NCT06321705
- Testing
- CS1
- Where
- Sweden
- Sponsor
- Cereno Scientific AB
End Stage Renal Failure on Dialysis, Hemodialysis Access Failure
Results of Cold Stored Allografts in Vascular Access
Vascular access creation in patients with renal failure requiring long-term hemodialysis can be a challenge when there is no more autologous material or in case of infection, in a population undergoing long term dialysis with a…
- Trial name
- RAVASC (NCT04446546)
- Testing
- Vascular access by pass using a cold stored venous allograft
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Central Hospital, Nancy, France
Advanced Solid Tumours
A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours
The purpose of this study is to allow continued adavosertib treatment of patients with advanced solid tumours participating in the adavosertib clinical pharmacology studies and to assess the continued safety and tolerability of…
- Trial name
- NCT04949425
- Testing
- Adavosertib
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 3 people
- Sponsor
- AstraZeneca
End Stage Renal Disease
Adenovirus Vascular Endothelial Growth Factor (VEGF) Therapy in Vascular Access - Novel Trinam AGainst Control Evidence
Patients in renal failure on hemodialysis depend on adequate and sustained vascular access. This can be achieved by surgical placement of a synthetic polytetrafluoroethylene (PTFE) graft.
- Trial name
- AdV-VANTAGE (NCT00895479)
- Testing
- Graft placement surgery plus Trinam therapy
- Where
- 12 sites in United States
- Volunteers
- 250 people
- Sponsor
- Ark Therapeutics Ltd
Arteriovenous Fistula, Arteriovenous Fistula Stenosis
Randomised Clinical Trial Comparing Drug-coated Balloon to Plain Balloon for All Peripheral AVF Stenosis
To compare the access circuit primary patency after Ranger drug-coated balloon angioplasty of arteriovenous fistula (AVF) stenosis with that after conventional balloon angioplasty
- Conditions
- Arteriovenous Fistula, Arteriovenous Fistula Stenosis, Dialysis Access Malfunction
- Trial name
- RANGER (NCT06553443)
- Testing
- Angioplasty of all peripheral AVF stenosis
- Where
- Singapore
- Volunteers
- 94 people
- Sponsor
- Singapore General Hospital
Hemodialysis Access Failure
Role of Regular Surveillance on Maintenance of Patency of an Arteriovenous Access
Chronic Kidney disease (CKD) is a worldwide public health problem that classified into five stages (1). End stage renal disease (CDK stage 5) patients require a well-functioning vascular access (VA) for successful hemodialysis…
- Trial name
- NCT04098159
- Testing
- duplex ultrasound
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Assiut University
Endovascular Treatments, Endovascular Surgery
A Prospective Randomized Study Comparing the Safety of Percutaneous and Open Brachial Access in the Endovascular Treatment of Peripheral Arterial Lesion
Endovascular treatment tends to replace open surgery in the management of peripheral arterial disease. Access via the common femoral artery remains the primary approach for peripheral arterial interventions.
- Conditions
- Endovascular Treatments, Endovascular Surgery, Peripheral Arterial
- Trial name
- BRAVO (NCT07573644)
- Testing
- Experimental arm, Procedure/Standard care
- Where
- 11 sites in France
- Volunteers
- 246 people
- Sponsor
- University Hospital, Brest
Kidney Failure
Aggrenox Prevention of Access Stenosis
The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts.
- Trial name
- GRAFT (NCT00067119)
- Testing
- Aggrenox
- Where
- 9 sites in United States
- Volunteers
- 649 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Differentiated Thyroid Cancer
An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
This Expanded Access Program (EAP) consists of a Prerandomization Phase and a Randomization Phase. Only subjects with radioiodine-refractory DTC who fulfill the eligibility criteria will be treated.
- Trial name
- NCT02211222
- Testing
- Lenvatinib
- Where
- 13 sites in United States
- Sponsor
- Eisai Inc.
Vascular Access Complication
Effects of Angiotensin Converting Enzyme Inhibitors on Patency of Arterio-Venous Fistulas: A Randomized Controlled Trial
Chronic kidney disease (CKD) is one of the leading health problems imbibing a major portion of health budget worldwide. The global prevalence of CKD is estimated to be 13.4% with approximately 5 to 7 million people needing renal…
- Trial name
- NCT05132712
- Testing
- Losartan Potassium, multi-vitamins
- Where
- Pakistan
- Volunteers
- 100 people
- Sponsor
- Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi
Neoplasms
Continued Treatment for Participants Enrolled in Studies of BXQ-350
This is a study to allow continued treatment for participants enrolled in studies of BXQ-350. This study is intended only for those who have completed the required study observation period or are still on treatment upon the…
- Trial name
- ETERNITI (NCT04404569)
- Testing
- BXQ-350
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Bexion Pharmaceuticals, Inc.
Non-Small Cell Lung Cancer
An EAP Treatment Protocol of Zipalertinib
"Only licensed physicians may submit an email inquiry/question about Taiho's Zipalertinib Expanded Access Program via email (Zipalertinib@parexel.com). If you are a patient or caregiver, do not email Parexel or Taiho.
- Trial name
- NCT07601399
- Testing
- Zipalertinib
- Sponsor
- Taiho Oncology, Inc.
Clear Cell Renal Cell Carcinoma
A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma
This is an open-label, multicenter, Phase 1a/1b study evaluating the theranostic pair 64Cu-PD-32766 Injection (PD-32766D) and 225Ac-PD-32766 Injection (PD-32766T) in adult patients with relapsed or refractory Carbonic Anhydrase…
- Trial name
- NCT07688187
- Testing
- PD-32766D (a Copper-64 [64Cu] labeled peptide), PD-32766T (an Actinium-225 [225Ac] labeled peptide)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- PeptiDream Inc.
Myelofibrosis
INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.
The primary objective of this study was to collect additional safety of INC424 in patients with Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis, who either received prior…
- Trial name
- JUMP (NCT01493414)
- Testing
- INC424
- Where
- 273 sites in Algeria, Argentina and 23 more
- Volunteers
- 2,233 people
- Sponsor
- Novartis Pharmaceuticals
Relapsed and/or Refractory Multiple Myeloma
A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple Myeloma
This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT0590 CAR T in patients with relapsed and/or refractory multiple myeloma.
- Trial name
- NCT05066022
- Testing
- CT0590 CAR T Cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- The First Affiliated Hospital of Soochow University